Core Viewpoint - MustGrow Biologics Corp. has successfully closed a non-brokered private placement, raising approximately $2.1 million through the sale of units, along with a repricing of warrants and a shares for debt settlement agreement [1][3][11] Group 1: LIFE Offering - The LIFE Offering consisted of 3,059,731 units sold at a price of $0.70 per unit, generating gross proceeds of approximately $2,141,812 [1] - Each unit includes one common share and one common share purchase warrant, with warrants exercisable for 60 months at an exercise price of $0.90 per share [2] - The net proceeds will be used for inventory production of the mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products, and general corporate purposes [3] Group 2: Warrant Repricing - The company has repriced 1,721,610 outstanding warrants from a previous private placement, reducing the exercise price from $1.90 to $0.90 per share [7][8] - The repriced warrants include an acceleration provision that allows for an earlier expiry if the share price exceeds $1.08 for ten consecutive trading days [9] - This repricing is pending final approval from the TSX Venture Exchange [10] Group 3: Shares for Debt Settlement - MustGrow is settling approximately $2,385,000 in outstanding principal under unsecured convertible debentures by issuing up to 3,407,134 shares at a deemed price of $0.70 per share [11] - The settlement also includes a cash payment for all accrued and unpaid interest [11] - The shares issued in this settlement will be subject to a statutory hold period of four months and one day [12] Group 4: Insider Participation and Compliance - Certain insiders participated in the LIFE Offering, purchasing a total of 285,716 units, which will be subject to a four-month hold period [13] - The participation of insiders in the LIFE Offering and other transactions is considered a related party transaction under Multilateral Instrument 61-101 [14] - The company is relying on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's market capitalization not exceeding 25% [14] Group 5: Company Overview - MustGrow Biologics Corp. provides innovative biological and regenerative agriculture solutions, focusing on eco-friendly alternatives to synthetic chemicals and fertilizers [15] - The company has a portfolio of approximately 109 patents and collaborates with agriculture companies like Bayer AG for commercialization [15] - MustGrow is publicly traded on the TSX Venture Exchange with approximately 58.9 million common shares outstanding [16]

Core Viewpoint - Silver47 Exploration Corp. has announced an increase in its brokered private placement offering to up to 28,572,000 units at a price of $0.70 per unit, aiming for gross proceeds of up to $20,000,400 due to strong investor demand [1][2]. Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $1.00 per share for 36 months [2]. - The company has granted the agents an option to increase the offering size by up to $3,000,060, potentially raising total gross proceeds to $23,000,460 if fully exercised [3]. Regulatory Compliance - The offering is being conducted in compliance with National Instrument 45-106, allowing sales to purchasers in all Canadian provinces except Quebec, under the "listed issuer financing exemption" [4]. Use of Proceeds - The net proceeds from the offering will be utilized for further exploration work on the company's projects and for general working capital purposes [2]. Closing Timeline - The company expects to close the offering around September 16, 2025, subject to regulatory approvals and the approval of the TSX Venture Exchange [6]. Agent Compensation - The company will pay the agents a cash commission of 6% of the gross proceeds and issue broker warrants exercisable for 36 months, equal to 6% of the units sold [7]. Company Overview - Silver47 Exploration Corp. focuses on developing silver-rich deposits in North America, with a combined resource totaling 236 million ounces of silver equivalent at an average grade of 334 g/t AgEq inferred and 10 million ounces at 333 g/t AgEq indicated [9].

Core Viewpoint - Silver47 Exploration Corp. has announced a brokered private placement to raise up to $14 million through the sale of units priced at $0.70 each, with the offering expected to close around September 16, 2025 [1][6]. Group 1: Offering Details - The offering consists of up to 20,000,000 units, each unit comprising one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $1.00 for 36 months [1][2]. - The company has granted agents an option to increase the offering size by up to $2.1 million [3]. - The offering is available to purchasers in all Canadian provinces except Quebec, relying on the "listed issuer financing exemption" [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for further exploration work on the company's projects and for general working capital purposes [2]. Group 3: Financial Terms - The company will pay agents a cash commission of 6% of the gross proceeds and issue broker warrants equal to 6% of the units sold, exercisable at $0.70 for 36 months [7]. Group 4: Company Overview - Silver47 Exploration Corp. focuses on developing silver-rich deposits in North America, with a combined resource totaling 236 million ounces of silver equivalent at an inferred grade of 334 g/t and 10 million ounces at an indicated grade of 333 g/t [9]. - The company operates in Alaska, Nevada, and New Mexico, which are known for their prolific mining jurisdictions [9].

Core Viewpoint - Tier One Silver Inc. has announced that its proposed private placement equity financing will not proceed, and the company will return any advanced funds to participating subscribers and their brokers [1]. Group 1: Financing and Future Plans - The company is actively seeking alternative financing options and will make an announcement once arrangements are made [2]. - The private placement was offered under a listed issuer financing exemption (LIFE) and was initially filed on June 23, 2025 [1]. Group 2: Company Overview - Tier One Silver is an exploration company focused on discovering valuable silver, gold, and copper deposits in Peru, with a primary focus on its flagship project, Curibaya [3]. - The management and technical teams of the company have a strong track record in capital raising, discovery, and monetization of exploration success [3].

Core Points - Terra Balcanica Resources Corp. has successfully closed the second and final tranche of its private placement, raising gross proceeds of C$302,581 through the issuance of 3,025,809 units at a price of C$0.10 per unit, bringing the total offering amount to C$1,117,495 [1][2][3] Financing Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at C$0.20 for a period of 24 months from the closing date [1] - The initial tranche of the offering was closed on July 11, 2025, raising C$814,914 through the issuance of 8,149,141 units [1] - Finders' fees of C$7,000 were paid, and 70,000 non-transferable finder's warrants were issued, also exercisable at C$0.20 for 24 months [1][2] Insider Participation - Kim Oishi, a director of the company, purchased 25,809 units in the final tranche, which is classified as a related party transaction [2] - The participation of the insider was approved by independent directors, and it does not materially change the percentage of outstanding securities owned by the insider [2] Regulatory Compliance - The private placement was conducted under the listed issuer financing exemption, and the securities issued are not subject to a hold period under Canadian securities laws [3] - However, the finder's warrants and the common shares issuable upon their exercise are subject to a hold period expiring on December 14, 2025 [3] Company Overview - Terra Balcanica is focused on polymetallic and energy metals exploration, targeting large-scale mineral systems in the Balkans and northern Saskatchewan, Canada [5] - The company holds a 90% interest in the Viogor-Zanik Project in Bosnia and has a 100% optioned portfolio of uranium-prospective licenses in Canada [5] - The company emphasizes responsible engagement with local communities and is committed to sustainable practices [5]

Core Insights - Ethos has partnered with Lifeforce to provide policyholders access to a comprehensive health optimization platform, which includes biomarker testing, longevity protocols, and health coaching [1][2][3] - The collaboration aims to combine financial protection with health optimization, allowing families to safeguard both their financial future and healthspan [1][3][4] Company Overview - Ethos is a leading life insurance technology company focused on democratizing access to life insurance and enhancing the purchasing experience through a fully digital application process [4][6] - Lifeforce is recognized as the largest longevity medicine platform, offering services such as at-home biomarker testing and access to expert physicians, with a significant number of members reporting health improvements [7] Partnership Details - The partnership provides Ethos policyholders with a $250 benefit towards Lifeforce's Diagnostic offering, which includes personalized treatment protocols and ongoing health coaching [1][2] - Ethos is enhancing its perks program to address policyholders' priorities, complementing its Indexed Universal Life insurance offering and estate planning tools [3][5] Industry Impact - The collaboration is expected to improve accessibility and affordability of life insurance and estate planning for millions of families, supported by industry-leading carriers [5]

Group 1: aTyr Pharma - aTyr Pharma is innovating in immunology by discovering that transfer RNA synthetases act as immune system modulators [3] - The lead drug, efzofitimod, is in phase 3 trials for pulmonary sarcoidosis, with results expected in Q3 2025 [4] - The market for sarcoidosis treatment is significant, with over 200,000 Americans affected, and efzofitimod has shown a 58% reduction in steroid use in earlier trials [5] - aTyr's current share price of $5.25 presents a potential upside of 376% based on analyst price targets [6] Group 2: Zeta Global - Zeta Global is transforming digital marketing through its AI Marketing Cloud, processing over 1 trillion signals monthly [7] - In Q2 2025, Zeta reported a 35% year-over-year revenue increase to $308 million, with adjusted EBITDA rising 52% to $59 million [8] - The global digital marketing spend is projected to reach $1.3 trillion by 2027, positioning Zeta to capture a growing market share [9] - Zeta's Agentforce AI enhances marketing efficiency, significantly reducing campaign optimization time [10] Group 3: Vertical Aerospace - Vertical Aerospace is pioneering urban transportation with its VX4 eVTOL aircraft, capable of reducing travel time significantly [11] - The VX4 completed the first airport-to-airport eVTOL flight in July 2025 and promises lower operating costs and zero emissions [12] - Vertical has a $6 billion conditional preorder book from major partners, with profitability projected by 2030 [13] - The current share price of $5.45 suggests significant upside potential compared to analyst targets of $11 [14] Group 4: Innovation Premium - These companies are addressing large-scale problems with innovative solutions, potentially transforming their respective industries [15]

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company's financial statements show increased assets, continued net losses, and sufficient liquidity, primarily from equity offerings Condensed Consolidated Balance Sheet Data (in thousands) | Balance Sheet Items | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $17,220 | $11,055 | | Total current assets | $87,492 | $81,954 | | **Total assets** | **$101,534** | **$96,830** | | Total current liabilities | $15,531 | $14,967 | | **Total liabilities** | **$26,878** | **$26,998** | | **Total stockholders' equity** | **$74,656** | **$69,832** | | Accumulated deficit | ($566,457) | ($532,046) | Condensed Consolidated Statements of Operations Data (in thousands, except per share data) | Income Statement Items | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $— | $— | $— | $235 | | Research and development | $15,384 | $13,973 | $27,198 | $27,337 | | General and administrative | $4,929 | $3,342 | $8,888 | $6,849 | | **Loss from operations** | **($20,313)** | **($17,315)** | **($36,086)** | **($33,951)** | | **Net loss attributable to aTyr** | **($19,531)** | **($16,306)** | **($34,411)** | **($31,797)** | | Net loss per share, basic and diluted | ($0.22) | ($0.23) | ($0.39) | ($0.46) | Condensed Consolidated Statements of Cash Flows Data (in thousands) | Cash Flow Items | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($29,314) | ($42,829) | | Net cash (used in) provided by investing activities | ($1,119) | $5,372 | | Net cash provided by financing activities | $36,525 | $21,130 | | **Net change in cash, cash equivalents and restricted cash** | **$6,092** | **($16,327)** | - The company has incurred net losses since its inception in 2005, with an accumulated deficit of **$566.5 million** as of June 30, 2025[26](index=26&type=chunk) - Management believes that existing cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** as of June 30, 2025, will be sufficient to meet material cash requirements for at least one year from the filing date of this report[28](index=28&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage pipeline, financial performance, and funding strategies, with key updates on efzofitimod [Overview](index=22&type=section&id=Overview) aTyr Pharma is a clinical-stage biotech advancing efzofitimod for ILD, with Phase 3 data expected soon, and other preclinical candidates - The lead therapeutic candidate is **efzofitimod**, a first-in-class biologic immunomodulator for treating interstitial lung disease (ILD)[70](index=70&type=chunk) - The global pivotal Phase 3 EFZO-FIT study for pulmonary sarcoidosis completed enrollment of 268 subjects in July 2024 and the last patient visit was completed in July 2025, with topline data expected in **mid-September 2025**[74](index=74&type=chunk) - The Phase 2 EFZO-CONNECT study in patients with SSc-ILD is ongoing, with interim data in June 2025 showing clinically important improvement in skin scores for **three of four** efzofitimod-treated patients[76](index=76&type=chunk) - The collaboration with Kyorin for efzofitimod in Japan has generated **$20.0 million** in payments to date, with up to an additional **$155.0 million** in potential milestones, plus royalties[77](index=77&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, accumulated deficit, and funding sources are discussed, highlighting reliance on equity offerings and changes in cash flow from operations - As of June 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** and an accumulated deficit of **$566.5 million**[82](index=82&type=chunk) - The company sold **8,771,725 shares** of common stock for net proceeds of approximately **$36.7 million** under its ATM Offering Program during the six months ended June 30, 2025[85](index=85&type=chunk) Summary of Net Cash Flow (in thousands) | Period | Net Cash Used in Operating Activities | Net Cash (Used in)/Provided by Investing Activities | Net Cash Provided by Financing Activities | | :--- | :--- | :--- | :--- | | **Six Months Ended June 30, 2025** | $(29,314) | $(1,119) | $36,525 | | **Six Months Ended June 30, 2024** | $(42,829) | $5,372 | $21,130 | - The decrease in net cash used in operating activities in H1 2025 compared to H1 2024 was primarily due to the timing of certain upfront efzofitimod manufacturing payments made in 2024[87](index=87&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Operating expenses increased in Q2 2025 due to higher R&D and G&A costs, with similar trends for the first six months, and further increases are anticipated Comparison of Operating Expenses for the Three Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$15,384** | **$13,973** | **$1,411** | | **Total general and administrative expenses** | **$4,929** | **$3,342** | **$1,587** | - The **$1.4 million** increase in Q2 2025 R&D expenses was primarily due to a **$1.0 million** increase in manufacturing costs for a potential BLA filing for efzofitimod[107](index=107&type=chunk) - The **$1.6 million** increase in Q2 2025 G&A expenses was mainly due to a **$1.2 million** increase in personnel and pre-commercialization costs[108](index=108&type=chunk) Comparison of Operating Expenses for the Six Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$27,198** | **$27,337** | **($139)** | | **Total general and administrative expenses** | **$8,888** | **$6,849** | **$2,039** | [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that this item is not applicable - Not applicable[116](index=116&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of the end of the quarter, with no material changes identified - Based on an evaluation as of the end of the quarter, the Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[118](index=118&type=chunk) - No changes in internal control over financial reporting were identified during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[119](index=119&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, though it may face routine claims in the ordinary course of business - aTyr Pharma is not a party to any material legal proceedings at this time[121](index=121&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to clinical trial success, manufacturing, capital requirements, third-party collaborations, and market volatility - The company may face substantial delays in clinical trials and may fail to demonstrate safety and efficacy, particularly for the EFZO-FIT study, as there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis[123](index=123&type=chunk)[133](index=133&type=chunk) - The company faces risks of manufacturing stoppages and challenges with its CDMOs, which could affect the clinical or commercial manufacture of its product candidates and regulatory activities required for a BLA submission[123](index=123&type=chunk)[146](index=146&type=chunk) - The company has a history of significant losses and will need to raise additional capital to fund operations, which may not be available on favorable terms or at all[123](index=123&type=chunk)[179](index=179&type=chunk) - The company depends on its collaboration with Kyorin for the development and commercialization of efzofitimod in Japan, and if this collaboration is not successful, the market potential may not be realized[126](index=126&type=chunk)[191](index=191&type=chunk) - The market price of the company's common stock has been and is likely to continue to be highly volatile[126](index=126&type=chunk)[295](index=295&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=105&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[345](index=345&type=chunk) [Defaults Upon Senior Securities](index=105&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[346](index=346&type=chunk) [Mine Safety Disclosures](index=105&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[347](index=347&type=chunk) [Other Information](index=105&type=section&id=Item%205.%20Other%20Information) During the quarter, the Chief Financial Officer and General Counsel adopted Rule 10b5-1 trading plans for pre-arranged security sales Executive Trading Arrangements (Rule 10b5-1) | Name and Title | Action | Adoption Date | Total Shares to be Sold (Max) | Expiration Date | | :--- | :--- | :--- | :--- | :--- | | Jill M. Broadfoot, Chief Financial Officer | Adoption | 6/16/2025 | 252,514 | 6/16/2026 | | Nancy E. Denyes, General Counsel | Adoption | 6/13/2025 | 100,000 | 6/13/2026 | [Exhibits](index=106&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Quarterly Report on Form 10-Q, including corporate governance and certification documents

Core Viewpoint - Vanguard Mining Corp. has successfully closed a non-brokered private placement of units, raising gross proceeds of $1,924,444.65 for exploration and working capital purposes [1][4]. Group 1: Offering Details - The LIFE Units were priced at $0.15 each, consisting of one common share and one-half of a transferable common share purchase warrant [1]. - Each whole LIFE Warrant allows the holder to purchase an additional share at $0.22 for 18 months, with an acceleration clause if the share price exceeds $0.32 for five consecutive trading days [1]. - The offering was made under the Listed Issuer Financing Exemption, allowing sales to purchasers in all Canadian provinces except Quebec, with no hold period for the securities [2]. Group 2: Financial Aspects - The company paid a finder fee of $131,755.60 and issued 878,371 non-transferable finders' warrants, each allowing the purchase of a common share at $0.22 for 18 months [3]. - The proceeds from the offering will be allocated to exploration programs on mineral properties and general working capital [4]. Group 3: Company Overview - Vanguard Mining Corp. is focused on discovering and developing strategic minerals, particularly uranium, in the U.S. and Paraguay [6]. - The company aims to identify and develop assets critical to the global energy transition, emphasizing responsible exploration and value creation [6].

Lake Victoria Gold Announces Non-Brokered LIFE Private Placement of Units and Concurrent Private Placement of Common Shares July 31, 2025 6:00 AM EDT | Source: Lake Victoria Gold Ltd. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2025) - Lake Victoria Gold Ltd. (TSXV: LVG) ("LVG" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "LIFE Private Placement") consisting of the issuance of units of the Company (the "Units") at a price of $0.175 pe ...